Literature DB >> 18506331

Management of advanced prostate cancer.

Rafael A Kaliks1, Auro Del Giglio.   

Abstract

Geriatricians and general practitioners often follow patients with metastatic prostate cancer. The epidemiology and basic treatment principles of metastatic prostate cancer are discussed aiming to update the topic for the non-oncologist. Hormone manipulation remains the basis of treatment, usually up to a second line of therapy. Selected cases are treated successfully with intermittent androgen ablation. When new hormone-independent clones arise, chemotherapy should be added to therapy that confers improved survival as well as better quality of life when based on taxanes. In specific situations, additional measures such as bisphosphonates and radiation therapy should be included in the treatment. As a rule, the public health system makes available the necessary medication to ensure treatment for the vast majority of patients in Brazil.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506331     DOI: 10.1590/s0104-42302008000200025

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  5 in total

1.  The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP.

Authors:  Bang-Xiang Xie; Hui Zhang; Lan Yu; Jian Wang; Bo Pang; Rui-Qin Wu; Xiao-Long Qian; Shan-Hu Li; Qing-Guo Shi; Le-Le Wang; Jian-Guang Zhou
Journal:  Asian J Androl       Date:  2010-02-02       Impact factor: 3.285

2.  Meta-analysis of archived DNA microarrays identifies genes regulated by hypoxia and involved in a metastatic phenotype in cancer cells.

Authors:  Michael Pierre; Benoît DeHertogh; Anthoula Gaigneaux; Bertrand DeMeulder; Fabrice Berger; Eric Bareke; Carine Michiels; Eric Depiereux
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

3.  Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Authors:  Natalia V Narizhneva; Natalia D Tararova; Petro Ryabokon; Inna Shyshynova; Anatoly Prokvolit; Pavel G Komarov; Andrei A Purmal; Andrei V Gudkov; Katerina V Gurova
Journal:  Cell Cycle       Date:  2009-12-13       Impact factor: 4.534

4.  Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.

Authors:  Fabiana Sélos Guerra; Daniel Alencar Rodrigues; Carlos Alberto Manssour Fraga; Patricia Dias Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

5.  Clinical significance of free-to-total prostate-specific antigen (PSA) ratio in advanced prostate cancer patients with PSA less than 0.1 ng/ml after hormone treatment.

Authors:  Dae Il Kim; Jae Mann Song; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2012-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.